Inhalatives Budesonid zur Therapie bei COVID-19
Standard
Inhalatives Budesonid zur Therapie bei COVID-19. / Kluge, S; Nitschmann, S; Scherer, M.
in: INTERNIST, Jahrgang 62, Nr. 8, 08.2021, S. 887-889.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
Kluge, S, Nitschmann, S & Scherer, M 2021, 'Inhalatives Budesonid zur Therapie bei COVID-19', INTERNIST, Jg. 62, Nr. 8, S. 887-889. https://doi.org/10.1007/s00108-021-01071-4
APA
Kluge, S., Nitschmann, S., & Scherer, M. (2021). Inhalatives Budesonid zur Therapie bei COVID-19. INTERNIST, 62(8), 887-889. https://doi.org/10.1007/s00108-021-01071-4
Vancouver
Kluge S, Nitschmann S, Scherer M. Inhalatives Budesonid zur Therapie bei COVID-19. INTERNIST. 2021 Aug;62(8):887-889. https://doi.org/10.1007/s00108-021-01071-4
Bibtex
@article{a3037fe65b984de39d0cf5f979afa272,
title = "Inhalatives Budesonid zur Therapie bei COVID-19",
author = "S Kluge and S Nitschmann and M Scherer",
year = "2021",
month = aug,
doi = "10.1007/s00108-021-01071-4",
language = "Deutsch",
volume = "62",
pages = "887--889",
journal = "INTERNIST",
issn = "0020-9554",
publisher = "Springer",
number = "8",
}
RIS
TY - JOUR
T1 - Inhalatives Budesonid zur Therapie bei COVID-19
AU - Kluge, S
AU - Nitschmann, S
AU - Scherer, M
PY - 2021/8
Y1 - 2021/8
U2 - 10.1007/s00108-021-01071-4
DO - 10.1007/s00108-021-01071-4
M3 - SCORING: Zeitschriftenaufsatz
C2 - 34191054
VL - 62
SP - 887
EP - 889
JO - INTERNIST
JF - INTERNIST
SN - 0020-9554
IS - 8
ER -
